BR112014005087A2 - método para detectar nucleossomas contendo nucleotídeos - Google Patents

método para detectar nucleossomas contendo nucleotídeos

Info

Publication number
BR112014005087A2
BR112014005087A2 BR112014005087A BR112014005087A BR112014005087A2 BR 112014005087 A2 BR112014005087 A2 BR 112014005087A2 BR 112014005087 A BR112014005087 A BR 112014005087A BR 112014005087 A BR112014005087 A BR 112014005087A BR 112014005087 A2 BR112014005087 A2 BR 112014005087A2
Authority
BR
Brazil
Prior art keywords
nucleotides
detecting
nucleotides containing
containing nucleotides
detecting nucleotides
Prior art date
Application number
BR112014005087A
Other languages
English (en)
Other versions
BR112014005087B1 (pt
Inventor
Vicent Micallef Jacob
Original Assignee
Singapore Volition Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Singapore Volition Pte Ltd filed Critical Singapore Volition Pte Ltd
Publication of BR112014005087A2 publication Critical patent/BR112014005087A2/pt
Publication of BR112014005087B1 publication Critical patent/BR112014005087B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
BR112014005087-2A 2011-09-01 2012-08-31 uso de uma base de dna associada com um nucleossoma livre de células como um biomarcador, métodos para detecção de uma base de dna, bem como métodos para detecção de um estado da doença em um animal ou ser humano, para avaliação da adaptação ao tratamento médico, e para monitoramento de um tratamento médico, e kit BR112014005087B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161530295P 2011-09-01 2011-09-01
GB1115095.0 2011-09-01
US61/530,295 2011-09-01
GBGB1115095.0A GB201115095D0 (en) 2011-09-01 2011-09-01 Method for detecting nucleosomes containing nucleotides
PCT/GB2012/052128 WO2013030577A1 (en) 2011-09-01 2012-08-31 Method for detecting nucleosomes containing nucleotides

Publications (2)

Publication Number Publication Date
BR112014005087A2 true BR112014005087A2 (pt) 2017-03-28
BR112014005087B1 BR112014005087B1 (pt) 2020-12-22

Family

ID=44882046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014005087-2A BR112014005087B1 (pt) 2011-09-01 2012-08-31 uso de uma base de dna associada com um nucleossoma livre de células como um biomarcador, métodos para detecção de uma base de dna, bem como métodos para detecção de um estado da doença em um animal ou ser humano, para avaliação da adaptação ao tratamento médico, e para monitoramento de um tratamento médico, e kit

Country Status (22)

Country Link
US (2) US10900064B2 (pt)
EP (2) EP3483608B1 (pt)
JP (1) JP6322845B2 (pt)
KR (1) KR102074528B1 (pt)
CN (1) CN104067124B (pt)
AU (1) AU2012300641B2 (pt)
BR (1) BR112014005087B1 (pt)
CA (1) CA2845993C (pt)
DK (1) DK2751568T3 (pt)
ES (1) ES2717659T3 (pt)
GB (1) GB201115095D0 (pt)
HK (1) HK1199760A1 (pt)
HR (1) HRP20190533T1 (pt)
HU (1) HUE043386T2 (pt)
MX (1) MX364410B (pt)
PL (1) PL2751568T3 (pt)
PT (1) PT2751568T (pt)
RU (2) RU2014112350A (pt)
SG (2) SG11201400270PA (pt)
TR (1) TR201904386T4 (pt)
WO (1) WO2013030577A1 (pt)
ZA (1) ZA201401295B (pt)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10083273B2 (en) 2005-07-29 2018-09-25 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
ES2620431T3 (es) 2008-08-04 2017-06-28 Natera, Inc. Métodos para la determinación de alelos y de ploidía
US10113196B2 (en) 2010-05-18 2018-10-30 Natera, Inc. Prenatal paternity testing using maternal blood, free floating fetal DNA and SNP genotyping
EP2854056A3 (en) 2009-09-30 2015-06-03 Natera, Inc. Methods for non-invasive pre-natal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
EP2572003A4 (en) 2010-05-18 2016-01-13 Natera Inc METHOD FOR NONINVASIVE PRANATAL PLOIDIE ASSIGNMENT
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
CN103608818B (zh) 2011-02-09 2017-12-08 纳特拉公司 非侵入性产前倍性识别装置
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
EP2775304A1 (en) * 2013-03-07 2014-09-10 Universitätsspital Basel Methods for detecting inflammatory disorder
US10262755B2 (en) 2014-04-21 2019-04-16 Natera, Inc. Detecting cancer mutations and aneuploidy in chromosomal segments
US10577655B2 (en) 2013-09-27 2020-03-03 Natera, Inc. Cell free DNA diagnostic testing standards
WO2015048535A1 (en) * 2013-09-27 2015-04-02 Natera, Inc. Prenatal diagnostic resting standards
CN106460070B (zh) 2014-04-21 2021-10-08 纳特拉公司 检测染色体片段中的突变和倍性
CN107002021B (zh) * 2014-09-30 2021-12-03 深圳华大基因科技有限公司 类风湿性关节炎的生物标记物及其用途
WO2016067029A1 (en) 2014-10-29 2016-05-06 Singapore Volition Pte Limited Method for the enrichment of circulating tumor dna
WO2016128383A1 (en) * 2015-02-10 2016-08-18 B.R.A.H.M.S Gmbh Free histone proteins as biomarkers
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
BR112017024747A2 (pt) 2015-05-18 2018-11-13 Karius Inc composições e métodos para enriquecer populações de ácidos nucleicos
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201518674D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
GB201518665D0 (en) * 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
CN107858416B (zh) * 2016-09-19 2021-05-28 深圳华大生命科学研究院 用于子宫内膜异位症检测的生物标志物组合及其应用
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
US10894976B2 (en) 2017-02-21 2021-01-19 Natera, Inc. Compositions, methods, and kits for isolating nucleic acids
CN107164508A (zh) * 2017-06-16 2017-09-15 上海易毕恩基因科技有限公司 用于检测肝癌的基因标志物及其用途
CN107385051A (zh) * 2017-08-04 2017-11-24 上海易毕恩生物技术有限公司 用于检测肝肿瘤良恶性的基因标志物、试剂盒及检测方法
FI3759249T3 (fi) * 2018-03-01 2023-10-11 Epicypher Inc Nukleosomimodifikaatioiden kvantitointi kemiallisesti määriteltyjä rekombinanttisia nukleosomeja käyttäen
US11525159B2 (en) 2018-07-03 2022-12-13 Natera, Inc. Methods for detection of donor-derived cell-free DNA
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
JP2022545821A (ja) 2019-08-27 2022-10-31 ベルジアン ボリション エスアールエル 循環ヌクレオソームを単離する方法
IL293342A (en) 2019-12-02 2022-07-01 Belgian Volition Srl Use of cell-free nucleosomes as biomarkers
KR20220158231A (ko) 2020-03-20 2022-11-30 벨지언 볼리션 에스알엘 무세포 뉴클레오솜 수준을 사용한 분류 방법
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
WO2023073179A1 (en) 2021-10-29 2023-05-04 Belgian Volition Srl Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2652901A1 (fr) 1989-10-11 1991-04-12 Pasteur Institut Complexes biologiques a base de nucleosomes, et leurs applications, notamment dans le domaine du diagnostic in vitro du lupus erythemateux dissemine (led).
US6630301B1 (en) * 1997-03-14 2003-10-07 The Penn State Research Foundation Detection of extracellular tumor-associated nucleic acid in blood plasma or serum
US6329179B1 (en) * 1996-03-26 2001-12-11 Oncomedx, Inc. Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer
EP1064549B1 (en) * 1998-03-18 2006-06-07 Roche Diagnostics GmbH Detection of apoptotic products
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
WO2005003381A1 (en) 2003-07-04 2005-01-13 Johnson & Johnson Research Pty. Limited Method for detection of alkylated cytosine in dna
GB0319376D0 (en) * 2003-08-18 2003-09-17 Chroma Therapeutics Ltd Histone modification detection
WO2005040814A1 (en) * 2003-10-14 2005-05-06 Cancer Research Technology Limited Methods and means of cancer detection by histone modification
CA2591717A1 (en) * 2004-12-16 2006-07-06 President And Fellows Of Harvard College Histone demethylation mediated by the nuclear amine oxidase homolog lsd1
DE102005034628B4 (de) * 2005-07-19 2007-08-23 Epigenomics Ag Verfahren zur Untersuchung von Cytosin-Methylierungen in DNA
WO2007049286A1 (en) * 2005-10-27 2007-05-03 Tata Memorial Centre A system for ex-vivo separation of apoptotic chromatin particles from blood or plasma
WO2007050706A2 (en) 2005-10-27 2007-05-03 University Of Missouri-Columbia Dna methylation biomarkers in lymphoid and hematopoietic malignancies
US20080311122A1 (en) 2005-11-28 2008-12-18 Medimmune, Llc Antagonists of Hmgb1 and/or Rage and Methods of Use Thereof
DE102006035600B3 (de) 2006-07-27 2007-11-08 Epigenomics Ag Verfahren zum Nachweis eines Methylierungsmusters
US20080131954A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
EP2147124A4 (en) * 2007-04-11 2010-07-14 Manuel Esteller EPIGENETIC BIOMARKERS FOR EARLY DETECTION, EFFICIENT TREATMENT AND RETENTION OF CANCER
US7608402B2 (en) * 2008-01-10 2009-10-27 Weiwei Li DNA methylation specific signal amplification
WO2009115313A1 (en) 2008-03-19 2009-09-24 Oryzon Genomics, S.A. Method and composition for methylation analysis
EP2865387B1 (en) 2008-11-21 2019-06-12 Københavns Universitet (University Of Copenhagen) Priming of an immune response
CN102460173A (zh) 2009-04-14 2012-05-16 加利福尼亚大学董事会 组蛋白修饰用于癌症的临床诊断和预后
CN102612652B (zh) 2009-08-06 2016-05-04 康奈尔大学 用于分子分析的设备和方法
EP2561367A1 (en) 2010-04-22 2013-02-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods for identifying an increased risk of systemic lupus erythematosus (sle) patients for developing renal manifestations
WO2011150974A1 (en) 2010-06-03 2011-12-08 Porto Conte Ricerche S.R.L. Biomarkers for lung neuroendocrine tumors
FI20105715A0 (fi) 2010-06-18 2010-06-18 Helsingin Yliopisto Asetyloituun HMGB1:een sitoutuva polyklonaalinen vasta-aine
CN101955998A (zh) * 2010-07-20 2011-01-26 赵英仁 一种血浆游离dna水平检测肝细胞坏死程度的方法
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
GB201115095D0 (en) 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
BR112014013082B1 (pt) * 2011-12-07 2021-02-02 Singapore Volition Pte Limited uso de um aduto nucleossomo-proteína e métodos para detectar a presença de um aduto nucleossomo-proteína
EP3401399B1 (en) 2012-03-02 2020-04-22 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
GB201303575D0 (en) 2013-02-28 2013-04-10 Singapore Volition Pte Ltd Method for detecting histone modifications in nucleosomes

Also Published As

Publication number Publication date
PL2751568T3 (pl) 2019-09-30
WO2013030577A1 (en) 2013-03-07
BR112014005087B1 (pt) 2020-12-22
RU2687483C2 (ru) 2019-05-14
PT2751568T (pt) 2019-04-16
US20140363812A1 (en) 2014-12-11
CN104067124A (zh) 2014-09-24
HK1199760A1 (en) 2015-07-17
US20200347435A1 (en) 2020-11-05
RU2017126701A3 (pt) 2019-01-31
MX2014002443A (es) 2014-10-13
AU2012300641A1 (en) 2014-03-06
SG11201400270PA (en) 2014-03-28
KR102074528B1 (ko) 2020-02-06
KR20140078637A (ko) 2014-06-25
CA2845993A1 (en) 2013-03-07
SG10201601153RA (en) 2016-03-30
MX364410B (es) 2019-04-25
EP2751568B1 (en) 2018-12-26
HRP20190533T1 (hr) 2019-06-28
RU2014112350A (ru) 2015-10-10
JP2014531573A (ja) 2014-11-27
CN104067124B (zh) 2018-05-04
ES2717659T3 (es) 2019-06-24
CA2845993C (en) 2020-10-13
GB201115095D0 (en) 2011-10-19
ZA201401295B (en) 2014-12-23
EP2751568A1 (en) 2014-07-09
JP6322845B2 (ja) 2018-05-16
EP3483608B1 (en) 2023-06-07
US10900064B2 (en) 2021-01-26
DK2751568T3 (en) 2019-04-15
RU2017126701A (ru) 2019-01-31
EP3483608A1 (en) 2019-05-15
AU2012300641B2 (en) 2017-09-28
TR201904386T4 (tr) 2019-05-21
HUE043386T2 (hu) 2019-08-28

Similar Documents

Publication Publication Date Title
BR112014005087A2 (pt) método para detectar nucleossomas contendo nucleotídeos
BR112014002252A2 (pt) métodos para a detecção de modificação de nucleotídeo
CO6801749A2 (es) Inhibidores de glucosilceramida sintasa
BR112014009066A2 (pt) dna triciclo-fosforotioato
DK2776833T3 (da) Cobinder-understøttet testfremgangsmåde
BR112013030354A2 (pt) método implementado por computador
EP2705162A4 (en) METHOD FOR DETECTING NUCLEIC ACID SEQUENCE VARIANTS
BR112014002562A2 (pt) método para monitoramento de fluidos
BR112014007958A2 (pt) método
PL2772549T3 (pl) Sposób wykrywania zmienności genetycznej
DE102012208877A8 (de) System zur Erfassung bewegter Objekte
BR112014001237A2 (pt) método
BR112014001765A2 (pt) método
DK2732131T3 (da) Positioneringsfremgangsmåde
DK2723947T3 (da) Centreringssystem
CU24164B1 (es) Inhibidores sustituidos de acetil-coa carboxilasa
BR112013030423A2 (pt) método para produção de biocoque
BR112014016066A8 (pt) método para detectar micro-organismos salmonella
BR112014009795A2 (pt) método
SG11201402865XA (en) Method for detecting protein-protein interaction
EP2674492A4 (en) METHOD FOR DETECTING NUCLEIC ACIDS
IT1403824B1 (it) Fanale per autoveicoli
NO20110531A1 (no) Instrumenteringssystem for bestemmelse av risikofaktorer
BR112013022920A2 (pt) método implementado por computador
ES1074173Y (es) Pieza para solados

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/08/2012, OBSERVADAS AS CONDICOES LEGAIS.